“Porem ipsum dolor sit amet, consectetur adipiscing elit. Nunc vulputate libero et velit interdum, ac aliquet odio mattis. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos.”
Daniela is an experienced drug developer who is passionate about advancing novel therapeutics through her scientific and business expertise.
Prior to joining General Proximity, Daniela held various high impact roles at Salarius Pharmaceuticals including Director of Targeted Protein Degradation (TPD) Development, Director of Research & Business Development, and Director of Corporate Development. In her role leading the TPD program she oversaw a cross-functional team culminating in the successful IND activation of SP-3164, Salarius’ first targeted protein degrader, and the identification and advancement of novel deuterated molecular glue degraders.
In earlier roles, she led business development activities including search and evaluation, transactions, and alliance management. She was also instrumental in raising over $50M from private and public investors to support the company’s growth. Additionally, Daniela brings clinical strategy and development expertise having assisted in the advancement of seclidemstat, a Phase 1/2 epigenetic drug being evaluated in patients with relapsed/refractory Ewing sarcoma.
Daniela completed her PhD in Biomedical Engineering at Georgia Institute of Technology and Emory University where her research focused on the development of nanoparticles for use as cancer diagnostic and targeted therapeutic agents. She received a M.S. at the University of Texas, where she was a Texas Venture Lab Associate involved in helping health and tech startups.At General Proximity, Daniela is leading partnering efforts and supporting the strategy and development of our internal pipeline, including IND preparation.
